BioSpace News Archive

Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, reaffirmed its commitment to job creation in Massachusetts.

IVERIC bio, Inc. announced that at the Company’s Virtual Symposium for Investors and Analysts, Arshad M. Khanani, MD, MA, of Sierra Eye Associates and Chairman of the GATHER2 Steering Committee, will discuss an accelerated enrollment timeline and patient retention, including injection fidelity, for GATHER2, the Company’s pivotal clinical trial of Zimura® in development for the treatment of geographic atrophy secondary to age-related macular degeneration.

Edesa Biotech, Inc. today reported that an independent Data and Safety Monitoring Board (DSMB) has completed an interim review of the company’s COVID-19 drug candidate.

Predictmedix Inc. announced today that it has filed a registration statement on Form 20-F to register its common shares with the United States Securities and Exchange Commission (the “SEC”).

CureDuchenne announces the launch of CureDuchenne Link , a centralized data hub that puts individuals with Duchenne and Becker firmly at the center of research.

Bioelectronica ® Corporation announced today that the company won the Innovation Showcase competition that was held at CYTO Virtual Interactive 2021.

IRISYS, LLC announced today that it has been issued U.S. Patent No. 11,033,530, Liposomal Anticancer Compositions.

Neovasc Inc. announced the publication of an article entitled, “Safety and Efficacy of Coronary Sinus Narrowing in Chronic Refractory Angina: Insights from the RESOURCE Study” in the International Journal of Cardiology.

Ampio Pharmaceuticals announced that the Company is expected to join the small cap Russell 2000® Index and the broad-market Russell 3000® Index at the conclusion of this year’s reconstitution of the Russell stock indexes, effective after the U.S. stock market opens on Monday, June 28, 2021, accordingly to a preliminary list of additions posted on June 4, 2021.

Nuevocor, a preclinical-stage biotech company specializing in gene therapy for cardiomyopathies, has announced the completion of an oversubscribed $24 million Series A financing round.